FDA panel recommends Pfizer’s Covid booster doses for people 65 and older after rejecting third shots for general population

0 7
An influential Food and Drug Administration advisory committee on Friday rejected a proposal to distribute booster shots of Pfizer and BioNTech's Covid-19 vaccine to the general public, paring back those plans to unanimously recommend the third shots to people age 65 and older and other vulnerable Americans."It's likely beneficial, in my opinion, for the elderly, and may eventually be indicated for the general population. I just don't think we're there yet in terms of the data," said Dr. Ofer Levy, a vaccine and infectious disease specialist at Boston Children's Hospital.The panel voted 16-2 against distributing the vaccines to Americans 16 and older, before unanimously embracing an alternate plan to give boosters to older Americans and those at a high risk of suffering from severe illness if they get the virus. That's previously included people with diabetes, heart disease, obesity and other so-called comorbidities.Pfizer's stock closed down 1.3%, while shares of BioNTech fel
Subscribe or log in to read the rest of this content.
Leave A Reply

Your email address will not be published.

At The Centre of Every Trade
$59.95/month